Clínica Baviera, S.A. (CBAV.MC)
EUR 34.0
(1.49%)
EUR 34.0
(1.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 67.21 Million EUR | 17.65% |
| 2022 | 56.15 Million EUR | 6.43% |
| 2021 | 53.48 Million EUR | 56.2% |
| 2020 | 34.06 Million EUR | 8.1% |
| 2019 | 31.53 Million EUR | 44.42% |
| 2018 | 21.93 Million EUR | 21.81% |
| 2017 | 18.02 Million EUR | 9.12% |
| 2016 | 16.5 Million EUR | 37.54% |
| 2015 | 11.87 Million EUR | 11.94% |
| 2014 | 10.69 Million EUR | -15.38% |
| 2013 | 11.81 Million EUR | 28.43% |
| 2012 | 8.81 Million EUR | -32.07% |
| 2011 | 14.52 Million EUR | -0.93% |
| 2010 | 14.66 Million EUR | 26.96% |
| 2009 | 11.55 Million EUR | -35.03% |
| 2008 | 17.77 Million EUR | -21.03% |
| 2007 | 22.77 Million EUR | -1.0% |
| 2006 | 22.73 Million EUR | 304.32% |
| 2005 | 17.62 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 20.96 Million EUR | -2.25% |
| 2024 Q1 | 21.45 Million EUR | 19.0% |
| 2023 Q3 | 11.75 Million EUR | -33.39% |
| 2023 Q2 | 17.65 Million EUR | -10.72% |
| 2023 Q1 | 19.77 Million EUR | 67.0% |
| 2023 Q4 | 18.02 Million EUR | 53.3% |
| 2023 FY | - EUR | 17.65% |
| 2022 Q2 | 15.29 Million EUR | -17.81% |
| 2022 FY | - EUR | 6.43% |
| 2022 Q4 | 11.83 Million EUR | 14.29% |
| 2022 Q3 | 10.35 Million EUR | -32.26% |
| 2022 Q1 | 18.6 Million EUR | 45.46% |
| 2021 Q1 | 14.54 Million EUR | 15.89% |
| 2021 FY | - EUR | 56.2% |
| 2021 Q4 | 12.79 Million EUR | 13.38% |
| 2021 Q3 | 11.28 Million EUR | -23.94% |
| 2021 Q2 | 14.83 Million EUR | 1.98% |
| 2020 Q4 | 12.55 Million EUR | 24.01% |
| 2020 Q2 | 4.97 Million EUR | -24.92% |
| 2020 FY | - EUR | 8.1% |
| 2020 Q3 | 10.12 Million EUR | 103.56% |
| 2020 Q1 | 6.62 Million EUR | -27.14% |
| 2019 Q3 | 5.76 Million EUR | -31.36% |
| 2019 Q1 | 8.36 Million EUR | 36.06% |
| 2019 Q2 | 8.39 Million EUR | 0.39% |
| 2019 Q4 | 9.08 Million EUR | 57.74% |
| 2019 FY | - EUR | 44.42% |
| 2018 Q1 | 7.16 Million EUR | 29.88% |
| 2018 Q3 | 2.93 Million EUR | -48.44% |
| 2018 FY | - EUR | 21.81% |
| 2018 Q4 | 6.14 Million EUR | 109.48% |
| 2018 Q2 | 5.69 Million EUR | -20.55% |
| 2017 Q2 | 4.54 Million EUR | -6.87% |
| 2017 FY | - EUR | 9.12% |
| 2017 Q4 | 5.51 Million EUR | 78.88% |
| 2017 Q3 | 3.08 Million EUR | -32.15% |
| 2017 Q1 | 4.87 Million EUR | 14.21% |
| 2016 Q1 | 5.21 Million EUR | 3.44% |
| 2016 FY | - EUR | 37.54% |
| 2016 Q4 | 4.27 Million EUR | 67.92% |
| 2016 Q3 | 2.54 Million EUR | -43.2% |
| 2016 Q2 | 4.47 Million EUR | -14.18% |
| 2015 Q4 | 5.04 Million EUR | 275.67% |
| 2015 Q1 | 3.32 Million EUR | -9.54% |
| 2015 Q2 | 2.29 Million EUR | -31.14% |
| 2015 Q3 | 1.34 Million EUR | -41.38% |
| 2015 FY | - EUR | 11.94% |
| 2014 Q4 | 3.67 Million EUR | 233.43% |
| 2014 Q2 | 1.79 Million EUR | -56.44% |
| 2014 Q1 | 4.11 Million EUR | 26.35% |
| 2014 FY | - EUR | -15.38% |
| 2014 Q3 | 1.1 Million EUR | -38.52% |
| 2013 Q1 | 4.06 Million EUR | 402.63% |
| 2013 Q3 | 62 Thousand EUR | -98.6% |
| 2013 Q4 | 3.25 Million EUR | 5156.92% |
| 2013 FY | - EUR | 28.43% |
| 2013 Q2 | 4.43 Million EUR | 9.26% |
| 2012 Q2 | 2.39 Million EUR | -33.26% |
| 2012 Q3 | 2.1 Million EUR | -12.13% |
| 2012 FY | - EUR | -32.07% |
| 2012 Q1 | 3.58 Million EUR | 0.0% |
| 2012 Q4 | -1.34 Million EUR | -163.9% |
| 2011 FY | - EUR | -0.93% |
| 2010 FY | - EUR | 26.96% |
| 2009 FY | - EUR | -35.03% |
| 2008 FY | - EUR | -21.03% |
| 2007 FY | - EUR | -1.0% |
| 2006 FY | - EUR | 304.32% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pangaea Oncology, S.A. | -1.55 Million EUR | 4416.403% |